{"id":123,"date":"2022-10-05T21:47:28","date_gmt":"2022-10-05T21:47:28","guid":{"rendered":"https:\/\/healthynewsusa.com\/?p=123"},"modified":"2022-10-05T21:47:33","modified_gmt":"2022-10-05T21:47:33","slug":"readers-and-tweeters-take-a-close-look-at-eye-care-and-white-mulberry-leaf","status":"publish","type":"post","link":"https:\/\/healthynewsusa.com\/?p=123","title":{"rendered":"Readers and Tweeters Take a Close Look at Eye Care and White Mulberry Leaf"},"content":{"rendered":"
\n

Letters to the Editor<\/a>\u00a0is a periodic feature. We\u00a0welcome all comments<\/a>\u00a0and will publish a selection. We edit for length and clarity and require full names.<\/em><\/p>\n

\n

Beware cataract surgery price-gouging: Private equity groups are scooping up eye care physician practices nationwide as money-making opportunities grow in medical eye care. By @LaurenWeberHP<\/a> #healthcare<\/a> @FortuneMagazine<\/a> https:\/\/t.co\/M2Ih4EZibA<\/a> via @khnews<\/a><\/p>\n

\u2014 Catherine Arnst (@cathyarnst) September 19, 2022<\/a><\/p><\/blockquote>\n

\u2014 Catherine Arnst, New York City<\/em><\/p>\n

Seeing Eye Care for What It Is<\/strong><\/p>\n

Thank you for telling the story of EyeCare Partners and others (Patients for Profit<\/a>: \u201cPrivate Equity Sees the Billions in Eye Care as Firms Target High-Profit Procedures<\/a>,\u201d Sept. 19). I went to EyeCare once. All I will say is I will never go back. I also went to a private-practice ophthalmologist. He should be ashamed of himself.<\/p>\n

Unfortunately, doctors themselves are ruining their profession\u2019s reputation. Please continue your stories to help us get at least halfway-decent care. I have no hope of it ever returning to good care.<\/p>\n

Your story brings out one old-time fact: Patients need to know that an overly busy doctor does not necessarily mean a \u201cgood\u201d doctor. Thank you again.<\/p>\n

\u2014 Hazel M. White, St. Louis<\/em><\/p>\n

\n

Yet another reminder that natural doesn’t mean safe.https:\/\/t.co\/oz17ubIKbz<\/a><\/p>\n

\u2014 Julie Doll (@JulieDoll_Ks) August 25, 2022<\/a><\/p><\/blockquote>\n

\u2014 Julie Doll, Garden City, Kansas<\/em><\/p>\n

American Herbal Products Association Weighs In on White Mulberry Leaf<\/strong><\/p>\n

The article written by Samantha Young on the untimely death of Lori McClintock, the wife of California congressman Tom McClintock, used this tragic event to challenge the robust regulation of dietary supplements by the federal government, despite there being no information in the report showing that Lori McClintock consumed white mulberry leaf as a dietary supplement (\u201cCongressman\u2019s Wife Died After Taking Herbal Remedy Marketed for Diabetes and Weight Loss<\/a>,\u201d Aug. 24).<\/p>\n

White mulberry leaf is normally administered for therapeutic use in the form of a tea or powdered extract, and the leaf is also used as a food ingredient. The two most comprehensive and authoritative English language compendia of traditional Chinese medicine \u2014 \u201cChinese Herbal Medicine\u201d and \u201cChinese Medical Herbology and Pharmacology\u201d \u2014 do not list any significant cautions or contraindications associated with mulberry leaf use.<\/p>\n

Most clinical trials studying white mulberry leaf report no adverse events, although some placebo-controlled studies have reported minor gastrointestinal issues \u2014 such as an upset stomach. A pooled analysis of these studies found no statistically significant difference in adverse events between participants receiving mulberry leaf and a placebo.<\/p>\n

The scientific consensus on the safety of white mulberry leaf is also reflected in the \u201cBotanical Safety Handbook,\u201d maintained by the American Herbal Products Association<\/a> and subject to strict standards of expert review. The contributing experts placed white mulberry leaf in the reference\u2019s safest classification based on an extensive review of the scientific literature. This classification process included a systematic literature review covering acute, short-term, and sub-chronic toxicity studies as well as in vitro, human, and animal research. The reviewers also searched for, and did not identify, any case reports in which white mulberry leaf produced a suspected drug or dietary supplement interaction.<\/p>\n

Lori McClintock\u2019s death certificate and the accompanying coroner\u2019s report identify the cause of death to be dehydration due to gastroenteritis due to adverse effects of white mulberry leaf ingestion. The coroner\u2019s report states that \u201ca partial plant leaf\u201d was present in the stomach and that \u201cportions of tablets and capsules [were not] discerned in the stomach.\u201d A University of California-Davis botanist identified the material as white mulberry leaf and stated, \u201cWhite mulberry is not toxic.\u201d<\/p>\n

While the death certificate declares \u201can autopsy with toxicology testing confirmed the cause of death,\u201d there is no toxicology test for white mulberry, and none of the toxicology testing performed for other unrelated drugs or common toxins revealed anything linking the death to white mulberry.<\/p>\n

The coroner\u2019s report did not explain whether or not there was evidence of any specific product(s) the deceased might have been taking, and ultimately how a conclusion was drawn to implicate white mulberry. Without this information, it is not possible to corroborate the coroner\u2019s findings and conclusions.<\/p>\n

Moreover, nearly half of the article is presented as a criticism of the robust federal regulation of dietary supplements, claiming that \u201cMcClintock\u2019s death underscores the risks of the vast, booming market of dietary supplements and herbal remedies.\u201d The article reports that two cases of people \u201csickened by mulberry supplements\u201d have been reported to the FDA since 2004 and that \u201c[a]t least one of those cases led to hospitalization.\u201d AHPA has reviewed the publicly available records of these two cases and notes the following significant details omitted from the article:<\/p>\n